^
    7d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=52, Enrolling by invitation, Janssen Research & Development, LLC | N=35 --> 52
    Enrollment change
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    9d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=120, Enrolling by invitation, Janssen Research & Development, LLC | N=80 --> 120
    Enrollment change
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    15d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=80, Enrolling by invitation, Janssen Research & Development, LLC | Trial completion date: Jan 2028 --> Oct 2028
    Trial completion date
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    10ms
    A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=85, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    JNJ-4681
    1year
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Apr 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    safimaltib (JNJ-6633) • JNJ-4681
    1year
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=80, Enrolling by invitation, Janssen Research & Development, LLC
    New P1 trial
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    over1year
    A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=85, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Apr 2025 | Trial primary completion date: Apr 2026 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    JNJ-4681
    over1year
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Jul 2025
    Trial completion date • Combination therapy
    |
    safimaltib (JNJ-6633) • JNJ-4681
    over1year
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2025 --> Dec 2026
    Trial completion date • Combination therapy
    |
    safimaltib (JNJ-6633) • JNJ-4681
    over1year
    A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=85, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2026 --> Dec 2026
    Trial completion date
    |
    JNJ-4681
    2years
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial primary completion date • Combination therapy
    |
    safimaltib (JNJ-6633) • JNJ-4681
    2years
    A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=85, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial primary completion date
    |
    JNJ-4681